Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3022856
IMC-3C5 · 1 trial · 1 indication
AEs include serious AEs (SAEs). AEs do not distinguish whether the events are treatment-emergent. A summary of serious and other non-serious AEs, regardless of causality, is presented in the Reported Adverse Event module.
A DLT was defined as any adverse event (National Cancer Institute \[NCI\]-Common Terminology Criteria for Adverse Events \[CTCAE\], Version 4.0) considered by the investigator to be definitely, probably, or possibly related to IMC-3C5, that occurred during the DLT Assessment Period (weeks 1 through 6) as follows: * Any Grade 3 or 4 hematologic toxicity * Any Grade 3 or 4 nonhematologic toxicity (excluding fatigue or anorexia lasting \<7 days, or Grade 3 nausea and/or vomiting that persisted for \<2 days following appropriate supportive care intervention)
| Arm | Type | Description |
|---|---|---|
| IMC-3C5 | EXPERIMENTAL | Participants receiving IMC-3C5 intravenously |
| Name | Type | Description |
|---|---|---|
| IMC-3C5 | BIOLOGICAL | Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week |
Inclusion Criteria: 1. Participant has histologic or cytologic confirmation of cancer 2. Participant has an advanced solid tumor that is refractory to standard therapy or for which no standard therapy is available 3. Participant has measurable or nonmeasurable disease according to Response Evaluati...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
IMC-3C5 is an investigational monoclonal antibody being developed by Eli Lilly and Company for the treatment of advanced solid tumors. It is designed to target FLT4, also known as VEGFR-3, a receptor involved in tumor biology. IMC-3C5 has been studied in a Phase 1 clinical trial in patients with neoplasms.
IMC-3C5 targets FLT4, also known as VEGFR-3. It is a monoclonal antibody that acts as an inhibitor of this receptor. FLT4 is a vascular endothelial growth factor receptor, and targeting it is the intended mechanism of action for this investigational oncology agent.
IMC-3C5 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker symbol LLY. The company is the sponsor of the clinical program evaluating this monoclonal antibody in patients with advanced solid tumors.
IMC-3C5 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 1 trial evaluating IMC-3C5 in subjects with advanced solid tumors has been completed.
IMC-3C5 has been evaluated in one clinical trial, NCT01288989, titled "A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors." This Phase 1 trial enrolled 44 participants, was conducted in the United States, and has been completed.
IMC-3C5 is being studied for the treatment of neoplasms, specifically advanced solid tumors. It is an investigational monoclonal antibody in Phase 1 development and is not approved for any indication. The completed Phase 1 trial enrolled 44 adult patients with advanced solid tumors.